<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03586687</url>
  </required_header>
  <id_info>
    <org_study_id>00008490</org_study_id>
    <nct_id>NCT03586687</nct_id>
  </id_info>
  <brief_title>Osteoarthritis Shoulder Injection Study</brief_title>
  <official_title>Clinical Outcomes Following Randomization of Steroid Concentration in Patients With Glenohumeral Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the most effective intraarticular steroid dose for&#xD;
      the treatment of glenohumeral osteoarthritis. The investigators aim to randomize patients&#xD;
      into low, medium, and high dose groups of injectable corticosteroids as these doses are&#xD;
      typically used in the standard of care for our patients. To date there has been no study to&#xD;
      evaluate which dose is most efficient with the fewest side effects for glenohumeral&#xD;
      osteoarthritis. The investigators objective will be to provide ultrasound guided&#xD;
      intraarticular glenohumeral injections of these randomized concentrations and to evaluate&#xD;
      pain and function before and following injection with the Shoulder Pain and Disability Index&#xD;
      (SPADI). The investigators hypothesize that the low dose steroid will provide equivalent&#xD;
      improvement of the pain and function to the medium and high doses, while minimizing side&#xD;
      effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoarthritis (OA) affects 54.4 million US adults and 23.7 million (43.5%) have&#xD;
      arthritis-attributable activity limitation. As the condition progresses, pain and functional&#xD;
      disability increase. Patients usually begin treatment with conservative measures including&#xD;
      physical therapy and administration of nonsteroidal anti-inflammatory drugs before obtaining&#xD;
      a corticosteroid injection. Corticosteroid injections have a patient-specific duration that&#xD;
      often provide relief for a month before the effects begin to taper with most individuals&#xD;
      returning to baseline by 2-3 months post injection.&#xD;
&#xD;
      Unfortunately, data on intraarticular injections is not robust and primarily focused on hip,&#xD;
      knee, and disease processes rather than the glenohumeral joint. For example, steroid&#xD;
      concentrations have been studied in adhesive capsulitis, where 20 and 40mg of triamcinolone&#xD;
      acenotide were used with no statistical significance between the two. When a placebo was&#xD;
      added, both doses were better than the placebo, but once again no difference was seen between&#xD;
      the two steroid concentrations. Another study, looking at knee osteoarthritis, found that&#xD;
      high dose steroids had a larger effect on duration, but other studies have shown no&#xD;
      difference in duration between the 40mg and 80mg concentration of triamcinolone acetonide.&#xD;
&#xD;
      Intraarticular injections do have adverse effects. Similar to steroids taken orally or&#xD;
      intravenously, intraarticular injections have a similar side effect profile. Fortunately,&#xD;
      intraarticular injections are localized, by the nature of the procedure, and the chances of&#xD;
      experiencing a significant side effect is rare. The most common side effects are steroid&#xD;
      flare, allergic reaction, facial erythema, hypo-pigmentation, fat pad necrosis, cutaneous&#xD;
      atrophy, and a transient increase in blood glucose. Some of the rare side effects have been&#xD;
      seen in case reports include idiopathic central serous chorioretinopathy, decrease in breast&#xD;
      milk production, sepsis, tendon rupture, and cataracts. In addition, the administration of&#xD;
      steroid injections are limited to being done every three months due to risk of weakening&#xD;
      tendons, and acceleration of cartilage loss.&#xD;
&#xD;
      There is a void of literature for understating the ideal injectable steroid concentrations in&#xD;
      glenohumeral osteoarthritis. Because of this, providers who perform intraarticular injections&#xD;
      tend to perform them based on prior training experience or anecdotal evidence. We aim to&#xD;
      evaluate the ideal steroid concentration that will maximize treatment effect for glenohumeral&#xD;
      osteoarthritis, but at the same time minimize side effects, and better train our future&#xD;
      providers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    insufficient rate of accrual&#xD;
  </why_stopped>
  <start_date type="Actual">July 13, 2018</start_date>
  <completion_date type="Actual">September 28, 2021</completion_date>
  <primary_completion_date type="Actual">September 28, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Overall SPADI scores at baseline compared to 2,4, and 6 months.</measure>
    <time_frame>baseline, 2, 4, and 6 months</time_frame>
    <description>The Shoulder Pain and Disability Index (SPADI) measures current shoulder pain and disability using a 13 item assessment. Scores range from 0-100 with higher scores indicating greater impairment or disability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess reactions to the steroid</measure>
    <time_frame>baseline, 2, 4, and 6 months</time_frame>
    <description>Adverse events will only include those that are determined to be related to steroid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Shoulder Arthroplasty following injection</measure>
    <time_frame>12 months</time_frame>
    <description>Shoulder arthroplasty is defined as total shoulder replacement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in overall SPADI scores for those receiving Shoulder Arthroplasty at 1 year</measure>
    <time_frame>12 months</time_frame>
    <description>The Shoulder Pain and Disability Index (SPADI) measures current shoulder pain and disability using a 13 item assessment. Scores range from 0-100 with higher scores indicating greater impairment or disability</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Glenohumeral Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20mg Triamcinolone with 3cc of 1% Lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40mg Triamcinolone with 3cc of 1% Lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>80mg Triamcinolone with 3cc of 1% Lidocaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone</intervention_name>
    <description>Ultrasound guided glenohumeral shoulder joint injection</description>
    <arm_group_label>20 mg</arm_group_label>
    <arm_group_label>40 mg</arm_group_label>
    <arm_group_label>80 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  An X-ray within a year with Radiographic evidence of OA&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Clinical diagnosis established due to symptoms that will include pain attributed to&#xD;
             glenohumeral osteoarthritis, pain with range of motion, and/or functional limitations&#xD;
             longer than 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous guided steroid injection of the glenohumeral joint within 3 months&#xD;
&#xD;
          -  Previous diagnosis of inflammatory arthritis, rotator cuff tear, or immunocompromised&#xD;
&#xD;
          -  Previous shoulder surgery&#xD;
&#xD;
          -  Allergy to steroid or lidocaine&#xD;
&#xD;
          -  A Kellgren and Lawrence classification of 1 or less on radiograph&#xD;
&#xD;
          -  Non-English Speaking&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cayce Onks, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State Hershey Medical Cen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Barbour KE, Helmick CG, Boring M, Brady TJ. Vital Signs: Prevalence of Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation - United States, 2013-2015. MMWR Morb Mortal Wkly Rep. 2017 Mar 10;66(9):246-253. doi: 10.15585/mmwr.mm6609e1.</citation>
    <PMID>28278145</PMID>
  </reference>
  <reference>
    <citation>McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, Hawker GA, Henrotin Y, Hunter DJ, Kawaguchi H, Kwoh K, Lohmander S, Rannou F, Roos EM, Underwood M. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar;22(3):363-88. doi: 10.1016/j.joca.2014.01.003. Epub 2014 Jan 24.</citation>
    <PMID>24462672</PMID>
  </reference>
  <reference>
    <citation>Godwin M, Dawes M. Intra-articular steroid injections for painful knees. Systematic review with meta-analysis. Can Fam Physician. 2004 Feb;50:241-8. Review. Erratum in: Can Fam Physician. 2009 Jun;55(6):590.</citation>
    <PMID>15000335</PMID>
  </reference>
  <reference>
    <citation>Arroll B, Goodyear-Smith F. Corticosteroid injections for osteoarthritis of the knee: meta-analysis. BMJ. 2004 Apr 10;328(7444):869. Epub 2004 Mar 23.</citation>
    <PMID>15039276</PMID>
  </reference>
  <reference>
    <citation>Gaujoux-Viala C, Dougados M, Gossec L. Efficacy and safety of steroid injections for shoulder and elbow tendonitis: a meta-analysis of randomised controlled trials. Ann Rheum Dis. 2009 Dec;68(12):1843-9. doi: 10.1136/ard.2008.099572. Epub 2008 Dec 3. Review.</citation>
    <PMID>19054817</PMID>
  </reference>
  <reference>
    <citation>Kim YS, Lee HJ, Lee DH, Choi KY. Comparison of high- and low-dose intra-articular triamcinolone acetonide injection for treatment of primary shoulder stiffness: a prospective randomized trial. J Shoulder Elbow Surg. 2017 Feb;26(2):209-215. doi: 10.1016/j.jse.2016.09.034. Epub 2016 Nov 30.</citation>
    <PMID>27914846</PMID>
  </reference>
  <reference>
    <citation>Yoon SH, Lee HY, Lee HJ, Kwack KS. Optimal dose of intra-articular corticosteroids for adhesive capsulitis: a randomized, triple-blind, placebo-controlled trial. Am J Sports Med. 2013 May;41(5):1133-9. doi: 10.1177/0363546513480475. Epub 2013 Mar 18.</citation>
    <PMID>23507791</PMID>
  </reference>
  <reference>
    <citation>Popma JW, Snel FW, Haagsma CJ, Brummelhuis-Visser P, Oldenhof HG, van der Palen J, van de Laar MA. Comparison of 2 Dosages of Intraarticular Triamcinolone for the Treatment of Knee Arthritis: Results of a 12-week Randomized Controlled Clinical Trial. J Rheumatol. 2015 Oct;42(10):1865-8. doi: 10.3899/jrheum.141630. Epub 2015 Aug 1.</citation>
    <PMID>26233499</PMID>
  </reference>
  <reference>
    <citation>Intra-articular injections for osteoarthritis of the knee. Med Lett Drugs Ther. 2006 Mar 27;48(1231):25-7.</citation>
    <PMID>16554699</PMID>
  </reference>
  <reference>
    <citation>Smuin DM, Seidenberg PH, Sirlin EA, Phillips SF, Silvis ML. Rare Adverse Events Associated with Corticosteroid Injections: A Case Series and Literature Review. Curr Sports Med Rep. 2016 May-Jun;15(3):171-6. doi: 10.1249/JSR.0000000000000259. Review.</citation>
    <PMID>27172081</PMID>
  </reference>
  <reference>
    <citation>McAlindon TE, LaValley MP, Harvey WF, Price LL, Driban JB, Zhang M, Ward RJ. Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial. JAMA. 2017 May 16;317(19):1967-1975. doi: 10.1001/jama.2017.5283.</citation>
    <PMID>28510679</PMID>
  </reference>
  <reference>
    <citation>Kegel G, Marshall A, Barron OA, Catalano LW, Glickel SZ, Kuhn M. Steroid injections in the upper extremity: experienced clinical opinion versus evidence-based practices. Orthopedics. 2013 Sep;36(9):e1141-8. doi: 10.3928/01477447-20130821-15.</citation>
    <PMID>24025004</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 21, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2018</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Cayce Onks</investigator_full_name>
    <investigator_title>Assistant Professor of Family and Community Medicine and Orthopedics and Rehabilitation</investigator_title>
  </responsible_party>
  <keyword>Ultrasound guided injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

